J Gynecol Oncol.  2008 Jun;19(2):129-134. 10.3802/jgo.2008.19.2.129.

The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix

• Choi IJ
• Cha MS
• Park ES
• Han MS
• Choi Y
• Je GH
• Kim HH

• KMID: 2129913
• DOI: http://doi.org/10.3802/jgo.2008.19.2.129

Abstract

OBJECTIVE
To evaluate the efficacy of concurrent chemoradiation (CCRT) using 5-flurouracil (5-FU) and cisplatin for locally advanced cervical cancer.
METHODS
We reviewed the medical records of 57 patients with locally advanced cervical cancer (stage IIB-IVA and bulky IB2-IIA tumor) who underwent the CCRT at Dong-A University Hospital from January 1997 to June 2007. The CCRT consisted of 5-FU, cisplatin and pelvic radiation. Every three weeks, 75 mg/m(2) cisplatin was administered on the first day of each cycle and 5-FU was infused at the dose of 1,000 mg/m(2)/d from the second day to the fifth day of each cycle. Radiation was administered to the pelvis at a daily dose of 1.8 Gy for five days per week until a medium accumulated dose reached to 50.4 Gy. If necessary, the radiation field was extended to include paraaortic lymph nodes. Consolidation chemotherapy was performed using 5-FU and cisplatin.
RESULTS
Fifty-seven patients were enrolled and the median follow-up duration was 53 months (range 7-120 months). The overall response rate was 91.5% (74% complete response and 17.5% partial response). The 5-year overall survival and 3-year progression free survival rates were 69.4% and 74.9%, respectively. During the follow-up period (median 23 months, range 7-60 months), fourteen patients were diagnosed as recurrent disease.
CONCLUSION
CCRT with 5-FU and cisplatin which is the primary treatment for patients with locally advanced cervical cancer was effective and well tolerated.

Keyword

Concurrent chemoradiation (CCRT); Locally advanced cervical cancer; Bulky cervical mass; Cisplatin; 5-fluorouracil

MeSH Terms

Cisplatin
Consolidation Chemotherapy
Disease-Free Survival
Fluorouracil
Follow-Up Studies
Humans
Lymph Nodes
Medical Records
Pelvis
Uterine Cervical Neoplasms
Cisplatin
Fluorouracil

Figure

• 

  Fig. 1 Disease free survival rate after local control.

• 

  Fig. 2 Overall survival rate after local control.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Jenal A, Siegel E, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006. 56:106–130.

3. Annual Report of Gynecologic Cancer Registry Program in Korea for 2002 (Jan. 1, 2002-Dec. 31, 2002). Korean J Obstet Gynecol. 2005. 48:1130–1180.

4. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet. 2001. 358:781–786.

5. Fu KK. Biological basis for the interaction of chemotherapeutic agents and radiation therapy. Cancer. 1985. 55:2123–2130.

6. Stehman FB, Bundy BN, Kucera PR, Deppe G, Reddy S, O'Connor DM. Hydroxyurea, 5-fluorouracil infusion, and cisplatin adjunct to radiation therapy in cervical carcinoma: A phase I-II trial of the Gynecologic Oncology Group. Gynecol Oncol. 1997. 66:262–267.

7. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999. 340:1144–1153.

8. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph node: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999. 17:1339–1348.

9. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999. 340:1154–1161.

10. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999. 340:1137–1143.

11. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation-therapy compared with pelvic radiation therapy alone as adjuvant therapy after radicalsurgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000. 18:1606–1613.

12. Coia L, Won M, Lanciano R, Marcial VA, Martz M, Hanks G. The patterns of care outcome study for cancer of the uterine cancer: Results of the second national practice survey. Cancer. 1990. 66:2451–2456.

13. Perez CA. Radiation therapy in the management of cancer of the cervix: Part II. Oncology. 1993. 7:61–76.

14. Jampolis S, Andras EJ, Fletcher GH. Analysis of sites and causes of failure of irradiation in invasive squamous cell carcinoma of the intact uterine cervix. Radiology. 1975. 115:681–685.

15. Simpson JR, Bauer M, Perez CA, Wasserman TH, Emami B, Doggett RL, et al. Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of an RTOG prospective randomized trial. Int J Radiat Oncol Biol Phys. 1989. 16:1483–1491.

16. Garcia-Angulo AH, Kagiya VT. Intratumoral and parametrial infusion of a 3-nitronidazole (AK-2123) in the radiotherapy of the uterine cervix cancer: Stage II-III preliminary positive results. Int J Radiat Oncol Biol Phys. 1992. 22:589–591.

17. Brady LW, Plenk HP, Hanley JA, Glassburn JR, Kramer S, Parker RG. Hyperbaric oxygen therapy for carcinoma of the cervix-stages IIB, IIIA, IIIB and IVA: Results of a randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981. 7:991–998.

18. Mitsuhashi N, Takahashi I, Takahashi M, Hayakawa K, Niibe H. Clinical study of radioprotective effects amifostine on long-term outcome for patients with cervical cancer. Int J Radiat Oncol Biol Phys. 1993. 26:407–411.

19. Maor MH, Gillespie BW, Peters LJ, Wambersie A, Griffin TW, Thomas FJ, et al. Neutron therapy in cervical cancer: Results of a phase III RTOG study. Int J Radiat Oncol Biol Phys. 1988. 14:885–891.

20. Hornback NB, Shupe RE, Shidnia H, Marshall CU, Lauer T. Advanced stage IIIB cancer of the cervix treatment by hyperthermia and radiation. Gynecol Oncol. 1986. 23:160–167.

21. Horiot JC, Le Fur R, N'guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992. 25:231–241.

22. Vokes EE, Weichselbaum RR. Concomitant Chemotherapy: Rational and clinical experience in patients with solid tumors. J Clin Oncol. 1990. 8:911–934.

23. Robert WS, Hoffman MS, Kavanaugh JJ, Fiorica JV, Greenberg H, Finan MA, et al. Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced squamous carcinoma of the lower female genital tract. Gynecol Oncol. 1991. 43:233–236.

24. Dionet C, Verrelle P. Curability of mouse L1210 leukemia by combination of 5-fluorouracil, cis-diamminedichloroplatinum (II), and low doses of gamma-rays. Cancer Res. 1984. 44:652–656.

25. Grem JL. Mechanisms of Action and Modulation of Fluorouracil. Semin Radiat Oncol. 1997. 7:249–259.

26. Britten RA, Evans AJ, Allalunis-Turner MJ, Pearcey RG. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys. 1996. 34:367–374.

27. Hamberger AD, Unal A, Gershenson DM, Fletcher GH. Analysis of the severe complication of irradiation of carcinoma of the cercix: Whole pelvis irradiation and intracavitary radium. Int J Radiat Oncol Biol Phys. 1983. 9:367–371.

28. Mancuso S, Smaniotto D, Benedetti Panici P, Favale B, Greggi S, Manfredi R, et al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol. 2000. 78:324–328.